Navigation Links
Study Presented at ACC Shows Treatment With ISIS 301012 Added to,Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C,Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C,Levels of Less Than 70 mg/dL

weeks of treatment with ISIS 301012.

The most common drug-related adverse events were painless mild to moderate injection site reactions. There was one possibly drug-related serious adverse event reported for the study: a patient in the 400 mg/dL cohort experienced fever more than 12 hours after receiving the first dose and subsequently dropped out of the study. This patient was not included in the per protocol analysis. In this high dose cohort, one patient had consecutive measurements of liver transaminases (ALT) above three times the upper limit of normal (3xULN); the maximal ALT observed in the study was 211 IU/L. Importantly, no patients evidenced liver chemistries that would suggest risk of liver injury (extremely high ALT or ALT elevations together with elevations in bilirubin greater than 2xULN). Patients in this study remain in follow-up.

According to John J.P. Kastelein, M.D., Ph.D., Chairman, Department of Vascular Medicine at the Academic Medical Center in Amsterdam, The Netherlands, lead investigator in the study, "ISIS 301012 continues to show exceptional promise as a new lipid-lowering agent. This study demonstrates that as an add-on therapy in patients on statins whose LDL-C levels are not adequately controlled, ISIS 301012 effectively enables patients to achieve target levels of LDL-C. This is an important clinical effect which, together its tolerability and lack of drug interactions, make ISIS 301012 an exciting drug for potential use in combination with other lipid-lowering therapies in the patients unable to derive sufficient benefit from available agents."

Mark Wedel, M.D., J.D., Isis' Chief Medical Officer, added, "ISIS 301012 is highly active and well tolerated in combination with statins, both in the routine high cholesterol population represented in this study, as well as in homozygous familial hypercholesterolemic patients on maximal concurrent lipid-lowering therapies. ISIS 301012 continues to perform to our highest ex
'"/>




Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
(Date:10/10/2008)..., Oct. 10 /- Boston Scienti...schedule of the Company,s major,events and press a...tion,s,(CRF) twentieth annual Transcatheter Cardio...which runs from October 12 to 17 in Washington, D....ange of safety and,efficacy data on its TAXUS(R) E...
(Date:10/9/2008)...s for Increased Sales and Marketing Efforts to Acc...ip(R) System, MENLO PARK, Calif., Oct. 9 /PRNewsw...t of devices for the percutaneous repair of cardia...cutive team with the appointment of,Sean Cleary as...eting and,Chris Richardson, as vice president of s...
(Date:10/8/2008)...a., Oct. 8 /PRNewswire-USNewswire/ -- The facts ar... from HIV/AIDS in,sub-Saharan Africa. More than 35...frica have already died of AIDS. The Foundation fo...ure the dying and their families,find compassion a...,s,innovative partnering initiative links African ...
(Date:10/8/2008)...ab Program to be Discontinued and Headcount to be ...its Portfolio Review; Zanolimumab Program to be D... of Employees, COPE... A/S (OMX: GEN),announced today that it is discont...In addition, as a result of a portfolio review and...
Breaking Medicine Technology:Boston Scientific to Release Broad Range of Clinical Trial Data on the Performance of TAXUS(R) Coronary Stent Systems at TCT 2008 2Boston Scientific to Release Broad Range of Clinical Trial Data on the Performance of TAXUS(R) Coronary Stent Systems at TCT 2008 3Boston Scientific to Release Broad Range of Clinical Trial Data on the Performance of TAXUS(R) Coronary Stent Systems at TCT 2008 4Boston Scientific to Release Broad Range of Clinical Trial Data on the Performance of TAXUS(R) Coronary Stent Systems at TCT 2008 5Boston Scientific to Release Broad Range of Clinical Trial Data on the Performance of TAXUS(R) Coronary Stent Systems at TCT 2008 6Evalve Expands Executive Leadership Team 2Evalve Expands Executive Leadership Team 3In celebration of World Hospice and Palliative Care Day, FHSSA Announces Seven New Partnerships Between U.S. Organizations and African Hospices 2In celebration of World Hospice and Palliative Care Day, FHSSA Announces Seven New Partnerships Between U.S. Organizations and African Hospices 3In celebration of World Hospice and Palliative Care Day, FHSSA Announces Seven New Partnerships Between U.S. Organizations and African Hospices 4Genmab A/S - Company Announcement: Genmab Reports Results of Portfolio 2Genmab A/S - Company Announcement: Genmab Reports Results of Portfolio 3Genmab A/S - Company Announcement: Genmab Reports Results of Portfolio 4The 7 Key Questions About the Schwarzenegger Nunez Health Care Compromise 620 1The 7 Key Questions About the Schwarzenegger Nunez Health Care Compromise 620 2The 7 Key Questions About the Schwarzenegger Nunez Health Care Compromise 620 3The 7 Key Questions About the Schwarzenegger Nunez Health Care Compromise 620 4The 7 Key Questions About the Schwarzenegger Nunez Health Care Compromise 620 5The 7 Key Questions About the Schwarzenegger Nunez Health Care Compromise 620 6New knock out gene model provides molecular clues to breast cancer 615 1New knock out gene model provides molecular clues to breast cancer 615 2New knock out gene model provides molecular clues to breast cancer 615 3Martek Announces Third Quarter 2007 Financial Results 613 1Martek Announces Third Quarter 2007 Financial Results 613 2Martek Announces Third Quarter 2007 Financial Results 613 3Martek Announces Third Quarter 2007 Financial Results 613 4Martek Announces Third Quarter 2007 Financial Results 613 5Martek Announces Third Quarter 2007 Financial Results 613 6Martek Announces Third Quarter 2007 Financial Results 613 7Martek Announces Third Quarter 2007 Financial Results 613 8Martek Announces Third Quarter 2007 Financial Results 613 9Martek Announces Third Quarter 2007 Financial Results 613 10Martek Announces Third Quarter 2007 Financial Results 613 11Martek Announces Third Quarter 2007 Financial Results 613 12IRIDEX Announces Closing of 245 0 Million Private Placement 608 1IRIDEX Announces Closing of 245 0 Million Private Placement 608 2IRIDEX Announces Closing of 245 0 Million Private Placement 608 3IRIDEX Announces Closing of 245 0 Million Private Placement 608 4
...akthrough Will Aid in Developing Therapies to Prev...RYVILLE, Calif., May 10, 2007 /PRNewswire/ -- Kine...lopment company, announced,today the first method ...es in animals through the pathway known as reverse...n mechanism by which excess,cholesterol can be rem...
...POLIS, France, May 11, 2007 /PRNewswire-FirstCall/...pdate on the phase 2a,study for NCX 1000, which is... Pharma Inc. A preliminary analysis of 11 patient...tension confirmed,the safety profile of NCX 1000 b...pport the continuation of this clinical trial. As ...
Other Medicine Technology:KineMed Presents Data Measuring Changes in Reverse Cholesterol,Transport for the First Time 2KineMed Presents Data Measuring Changes in Reverse Cholesterol,Transport for the First Time 3NicOx Provides an Update on the Phase 2a Study for NCX 1000,Conducted With Axcan 2NicOx Provides an Update on the Phase 2a Study for NCX 1000,Conducted With Axcan 3
(Date:10/13/2008)...eading Content Rights Management System, Supports... Content Spend, WEST CHESTER, Pa., Oct. 13 /PRNew...ding global pharmaceutical manufacturer has integr...primary platform for the,secure distribution, data...cs for their new product video content. Imperium i...
(Date:10/13/2008)...swire/ -- The National Coalition for,Quality Color...ncerns over,the National CT Colonography Study pub...Medicine. The evidence must be closely evaluated, ...y is not without significant,potential risks. The ...py,remains the "Gold Standard" for colorectal canc...
(Date:10/13/2008)...blem in daily life, survey shows, PORTLAND, Ore.,...three-quarters of people living with psoriasis say...e, according to a National Psoriasis,Foundation 20...viduals with psoriasis and psoriatic arthritis,als...ly lives, shapes their,feelings about themselves a...
(Date:10/13/2008)...swire/ -- During the Pri-Med New York,conference a...are providers,took a 20-question quiz prepared by ...n Somerset, NJ. The quiz tested basic knowledge of..., EMR software, and healthcare,administration., T... The average number,of correct answers was only 7....
Breaking Medicine News(10 mins):Health News:Global Pharma Integrates Imperium(TM) to Support Launch Content ROI Initiatives! 2Health News:National Coalition for Quality Colorectal Cancer Screening and Care Conveys Concerns over CT Colonography 2Health News:National Coalition for Quality Colorectal Cancer Screening and Care Conveys Concerns over CT Colonography 3Health News:National Psoriasis Foundation Releases 2008 Study Results 2Health News:MTBC Practice Management Quiz Sends Message to Doctors: There is Real Room for Improvement or a Need to Outsource 2
... the womb! Mothers can prevent the occurrence of c...e course of life //just by having a nutritious die...vegetables like cabbage and broccoli. A new study ...titute at Oregon State University, done with labor...
...nics were developed by scientists with a vision to... all defective genes from the gene pool. // But no...ade to order. Though it sounds absurd, ‘why should...To some parents with disabilities like deafness an...
...indicated that blood tests which were designed to ... good //as cholesterol tests , or blood pressure t... veritable risk indicator. Doctors have been mak...d which they interpreted as indicators of a heart ...
..., effectiveness and reliability of LASIK and LASEK...etween the two types of laser eye// surgery. The ...researcher, is published in the December 2006 issu...f Ophthalmology. "Although there have been many s...
Other Medicine News:Health News:Cancer Prevention Begins During Pregnancy 2Health News:Cancer Prevention Begins During Pregnancy 3Health News:Can Defective Babies Be Made To Order? 2Health News:Study Compares LASIK and LASEK Eye Surgery 2
Gentamicin Reagent Solution (10 mg/ml) liquid
LB Agar plates with 0.1mM EDTA.
Luria bertani broth: 1.0% Tryptone, 0.5% Yeast Extract, 1.0% Sodium Chloride.
2.5% Soytone, 4.8% Yeast Extract, 0.025% Magnesium Sulfate, 130mM Calcium Chloride.
Medicine Products: